ClearPoint Neuro (NASDAQ:CLPT) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

ClearPoint Neuro (NASDAQ:CLPT) had its price target upped by investment analysts at Stifel Nicolaus from $19.00 to $25.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 110.26% from the stock’s previous close.

A number of other equities research analysts have also issued reports on CLPT. B. Riley raised their price target on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Lake Street Capital lifted their target price on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st.

ClearPoint Neuro Stock Down 0.7 %

CLPT opened at $11.89 on Tuesday. ClearPoint Neuro has a 52 week low of $5.11 and a 52 week high of $19.22. The firm has a 50-day simple moving average of $15.67 and a two-hundred day simple moving average of $14.04. The company has a market capitalization of $328.54 million, a PE ratio of -17.23 and a beta of 1.06.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $7.77 million for the quarter, compared to the consensus estimate of $8.23 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. As a group, sell-side analysts expect that ClearPoint Neuro will post -0.66 earnings per share for the current year.

Institutional Trading of ClearPoint Neuro

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of ClearPoint Neuro by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 1,248,393 shares of the company’s stock valued at $19,200,000 after acquiring an additional 5,400 shares during the last quarter. Millennium Management LLC raised its stake in shares of ClearPoint Neuro by 5.0% during the 4th quarter. Millennium Management LLC now owns 289,150 shares of the company’s stock valued at $4,447,000 after buying an additional 13,866 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in shares of ClearPoint Neuro by 27.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 288,409 shares of the company’s stock valued at $4,436,000 after buying an additional 62,889 shares during the period. Geode Capital Management LLC lifted its holdings in shares of ClearPoint Neuro by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 287,294 shares of the company’s stock valued at $3,222,000 after buying an additional 4,170 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of ClearPoint Neuro in the fourth quarter worth about $3,814,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.